Clinical efficacy of atezolizumab plus bevacizumab in the first-line treatment of advanced huge hepatocellular carcinoma

VernacularTitle:阿替利珠单克隆抗体联合贝伐珠单克隆抗体一线治疗晚期巨块型肝细胞癌的临床疗效
Author: Yan ZHANG ¹ ; Shan ZHONG ; Huan DENG ; Renjun WAN ; Wenqiang LUO ; Zhi ZHOU
Author Information

1. 重庆医科大学附属第二医院感染病科，重庆　400010
Keywords: Liver neoplasms; Immunotherapy; Target therapy; Atezolizumab; Beva-cizumab; Clinical efficacy
From: Chinese Journal of Digestive Surgery 2022;21(S1):35-40
CountryChina
Language:Chinese
Abstract: The incidence and mortality of hepatocellular carcinoma (HCC) is very high in China, which seriously threatens human life and health. There were limited treatment options for advanced HCC in the past, and the overall survival of HCC patients was poor. In recent years, immuno-therapy and targeted therapy have been recommended as effective means for the treatment of advan-ced HCC. The authors report a case of advanced huge HCC which has achieved a maintained partial response for 6 months after the treatment of atezolizumab combined with bevacizumab. The tumor shrunk by 32.4% and 47.5% after 3 and 6 months of treatment. Besides, the alpha-fetoprotein and abnormal tumor protein value of the patient continued to decrease without any adverse reactions. The treatment is evaluated as partial response and patients has a good short-term effect.